<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Taysha Gene Therapies Inc — News on 6ix</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc</link>
<description>Latest news and press releases for Taysha Gene Therapies Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 21:21:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/taysha-gene-therapies-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cde678dffbe2df11e3a2.webp</url>
<title>Taysha Gene Therapies Inc</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc</link>
</image>
<item>
<title>Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-to-present-new-preclinical-data-supporting-construct-design-of-tsha-102-for-rett-syndrome-at-the-asgct-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-to-present-new-preclinical-data-supporting-construct-design-of-tsha-102-for-rett-syndrome-at-the-asgct-2026-annual-meeting</guid>
<pubDate>Mon, 27 Apr 2026 21:21:00 GMT</pubDate>
<description>In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration MiniMeCP2 is functionally comparable to full-length MeCP2 across molecular and biochemical functions, with both proteins exhibiting comparable, stable expression in neuronal cells Data further validate the selection of scAAV9 and miniMeCP2 in the TSHA-10</description>
</item>
<item>
<title>Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2</description>
</item>
<item>
<title>Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-to-release-full-year-2025-financial-results-and-host-conference-call-and-webcast-on-march-19-8</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-to-release-full-year-2025-financial-results-and-host-conference-call-and-webcast-on-march-19-8</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused</description>
</item>
<item>
<title>Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Fri, 06 Feb 2026 05:00:00 GMT</pubDate>
<description>DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and</description>
</item>
<item>
<title>Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal-gene-therapy-program</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal-gene-therapy-program</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6</description>
</item>
<item>
<title>Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis</description>
</item>
<item>
<title>Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-release-third-quarter-2025-financial-results-and-host</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-release-third-quarter-2025-financial-results-and-host</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused</description>
</item>
<item>
<title>Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-regains-full-rights-lead-tsha-102-program-clinical-evaluation</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-regains-full-rights-lead-tsha-102-program-clinical-evaluation</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving</description>
</item>
<item>
<title>Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-presents-new-supplemental-data-analysis-part-reveal-phase-1-2</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-presents-new-supplemental-data-analysis-part-reveal-phase-1-2</guid>
<pubDate>Thu, 09 Oct 2025 04:00:00 GMT</pubDate>
<description>Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined</description>
</item>
<item>
<title>Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-fda-breakthrough-therapy-designation-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-fda-breakthrough-therapy-designation-and-provides</guid>
<pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
<description>Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of</description>
</item>
<item>
<title>Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-second-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-second-quarter-2025-financial-results-and-provides</guid>
<pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
<description>Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter</description>
</item>
<item>
<title>Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-release-second-200500006</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-release-second-200500006</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, at 8:30 AM Eastern Time. C</description>
</item>
<item>
<title>Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-details-oral-presentations-2025-irsf-rett-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-details-oral-presentations-2025-irsf-rett-syndrome</guid>
<pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
<description>Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase</description>
</item>
<item>
<title>Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-pivotal-part-b-trial-design-details-tsha-102-rett</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-pivotal-part-b-trial-design-details-tsha-102-rett</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental</description>
</item>
<item>
<title>Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-pricing-public-offering-common-stock-and-pre-funded-0</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-pricing-public-offering-common-stock-and-pre-funded-0</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on</description>
</item>
<item>
<title>Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-proposed-public-offering-common-stock-and-pre-0</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-announces-proposed-public-offering-common-stock-and-pre-0</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on</description>
</item>
<item>
<title>Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-first-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-first-quarter-2025-financial-results-and-provides</guid>
<pubDate>Thu, 15 May 2025 04:00:00 GMT</pubDate>
<description>Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised</description>
</item>
<item>
<title>Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-release-first-quarter-2025-financial-results-and-host</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-release-first-quarter-2025-financial-results-and-host</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing</description>
</item>
<item>
<title>Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-full-year-2024-financial-results-and-provides-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-reports-full-year-2024-financial-results-and-provides-corporate</guid>
<pubDate>Wed, 26 Feb 2025 05:00:00 GMT</pubDate>
<description>High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult</description>
</item>
<item>
<title>Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26</title>
<link>https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-release-full-year-2024-financial-results-and-host-conference</link>
<guid isPermaLink="true">https://6ix.com/company/taysha-gene-therapies-inc/news/taysha-gene-therapies-release-full-year-2024-financial-results-and-host-conference</guid>
<pubDate>Wed, 19 Feb 2025 05:00:00 GMT</pubDate>
<description>DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing</description>
</item>
</channel>
</rss>